Magnetic nanoparticles for cancer diagnosis and therapy

Pharmaceutical Research

Volumn 29, Issue 5, 2012, Pages 1180-1188

  Yigit, Mehmet V ^a   Moore, Anna ^a   Medarova, Zdravka ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Diagnosis; Drug delivery gene delivery; Iron oxide nanoparticle; Magnetic nanoparticle; Molecular imaging; MRI; Nanomedicine; siRNA; Therapy

Indexed keywords

AMPHIPHILIC BLOCK COPOLYMER; CONTRAST MEDIUM; COPOLYMER; DOXORUBICIN; IRON OXIDE NANOPARTICLE; MAGNETIC NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CELL TRACKING; COMPLEX FORMATION; CONJUGATION; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMAGE ANALYSIS; IMAGE GUIDED RADIOTHERAPY; IRON METABOLISM; LUNG CANCER; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNTHESIS;

HUMANS; IRON; MAGNETICS; METAL NANOPARTICLES; NEOPLASMS;

EID: 84862667715     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0679-7     Document Type: Review

References (64)

1. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int J Nanomedicine. 2010;5:803-9.
2. Kievit FM, Zhang M. Surface engineering of iron oxide nano-particles for targeted cancer therapy. Acc Chem Res 2011;44:853-62.
3. Gupta AK, Wells S. Surface-modified superparamagnetic nano-particles for drug delivery: preparation, characterization, and cytotoxicity studies. IEEE Trans NanoBiosci. 2004;3:66-73.
4. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D: Appl Phys. 2003;36:R167-81.
5. Anzai Y, Piccoli CW, Outwater EK, et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology. 2003;228:777-88.
6. Kim HS, Oh SY, Joo HJ, Son KR, Song IC, Moon WK. The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells. NMR Biomed. 2010;23:514-22.
7. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJG. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:386-93.
8. Saokar A, Gee MS, Islam T, Mueller PR, Harisinghani MG. Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10. Clin Imag. 2010;34:448-52.
9. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19:1599-605.
10. Babes L, Denizot B, Tanguy G, Le JJJ, Jallet P. Synthesis of iron oxide nanoparticles used as MRI contrast agents: a parametric study. J Colloid Interface Sci. 1999;212:474-82.
11. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17:484-99.
12. Sjogren CE, Briley-Saebo K, Hanson M, Johansson C. Magnetic characterization of iron oxides for magnetic resonance imaging. Magn Reson Med. 1994;31:268-72.
13. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron oxides for MR imaging. Adv Drug Delivery Rev. 1995;16:321-33.
14. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity. Magn Reson Imag. 1988;6:647-53.
15. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
16. Sun C, Du K, Fang C, et al. PEG-Mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano. 2010;4:2402-10.
17. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553-61.
18. Corsi F, De Palma C, Colombo M, et al. Towards ideal magnetofluorescent nanoparticles for bimodal detection of breast-cancer cells. Small. 2009;5:2555-64.
19. Pittet MJ, Swirski FK, Reynolds F, Josephson L, Weissleder R. Labeling of immune cells for in vivo imaging using magnetofluorescent nanoparticles. Nat Protoc. 2006;1:73-9.
20. Wang P, Yigit MV, Medarova Z, et al. Combined small interfering RNA therapy and in vivo magnetic resonance imaging in islet transplantation. Diabetes. 2011;60:565-71.
21. Bae KH, Kim YB, Lee Y, Hwang J, Park H, Park TG. Bioinspired synthesis and characterization of gadolinium-labeled magnetite nanoparticles for dual contrast T1- and T2-weighted magnetic resonance imaging. Bioconjugate Chem. 2010;21:505-12.
22. Yang X, Hong H, Grailer JJ, et al. cRGD-functionalized, DOX-conjugated, and Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011;32:4151-60.
23. Yigit MV, Zhu L, Ifediba MA, et al. Noninvasive MRI-SERS imaging in living mice using an innately bimodal nanomaterial. ACS Nano. 2011;5:1056-66.
24. Chen FH, Zhang LM, Chen QT, Zhang Y, Zhang ZJ. Synthesis of a novel magnetic drug delivery system composed of doxorubicin-conjugated Fe3O4 nanoparticle cores and a PEG-functionalized porous silica shell. Chem Commun (Camb). 2010;46:8633-5.
25. Gaihre B, Khil MS, Kim HY. In vitro anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide nanoparticles. J Microencapsul. 2011;28:286-93.
26. Kievit FM, Wang FY, Fang C, et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J Contr Release. 2011;152:76-83.
27. Lee JH, Lee K, Moon SH, Lee Y, Park TG, Cheon J. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed. 2009;48:4174-9.
28. Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr Drug Deliv. 2011;8:59-69.
29. Zhang H, Lee MY, Hogg MG, Dordick JS, Sharfstein ST. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano. 2010;4:4733-43.
30. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032-8.
31. Lee CS, Lee H, Westervelt RM. Microelectromagnets for the control of magnetic nanoparticles. Appl Phys Lett. 2001;79:3308-10.
32. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev. 1995;16:195-214.
33. Gupta AK, Curtis ASG. Lactoferrin and ceruloplasmin derivatized superparamagnetic iron oxide nanoparticles for targeting cell surface receptors. Biomaterials. 2004;25:3029-40.
34. Tourinho F, Franck R, Massart R, Perzynski R. Synthesis and magnetic properties of manganese and cobalt ferrite ferrofluids. Prog Colloid Polym Sci. 1989;79:128-34.
35. Kim DK, Zhang Y, Voit W, Rao KV, Muhammed M. Synthesis and characterization of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J Magn Magn Mater. 2001;225:30-6.
36. Portet D, Denizot B, Rump E, Lejeune J-J, Jallet P. Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents. J Colloid Interface Sci. 2001;238:37-42.
37. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging. Physicochemical characteristics and clinical applications. A review. J Drug Target. 1998;6:167-74.
38. Kim DK, Zhang Y, Voit W, et al. Superparamagnetic iron oxide nanoparticles for bio-medical applications. Scr Mater. 2001;44:1713-7.
39. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319-31.
40. Bean CP, Livingston JD. Superparamagnetism. J Appl Phys. 1959;30:120S-9S.
41. Tartaj P, Morales MdP, Veintemillas-Verdaguer S, Gonzalez- Carreno T, Serna CJ. The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys. 2003;36: R182-97.
42. Goya GF, Berquó TS, Fonseca FC, Morales MP. Static and dynamic magnetic properties of spherical magnetite nanoparticles. J Appl Phys. 2003;94:3520-8.
43. Jeong U, Teng X, Wang Y, Yang H, Xia Y. Superparamagnetic colloids: controlled synthesis and niche applications. Adv Mater. 2007;19:33-60.
44. Mikhaylova M, Kim DK, Bobrysheva N, et al. Superparamagnetism of magnetite nanoparticles: dependence on surface modification. Langmuir. 2004;20:2472-7.
45. Bedanta S, Kleemann W. Supermagnetism. J Phys D: Appl Phys 2009;42 013001.
46. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010;70:7553-61.
47. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In-vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372-7.
48. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res. 2009;69:1182-9.
49. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252-65.
50. Ferrari M. Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol. 2010;7:485-6.
51. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104:15549-54.
52. Kievit FM, Veiseh O, Fang C, et al. Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano. 2010;4:4587-94.
53. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 2009;16:217-26.
54. Agrawal A, Min DH, Singh N, et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 2009;3:2495-504.
55. Yang J, Lee CH, Ko HJ, et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl. 2007;46:8836-9.
56. Yu MK, Jeong YY, Park J, et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl. 2008;47:5362-5.
57. Lim E-K, Huh Y-M, Yang J, Lee K, Suh J-S, Haam S. pH-Triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv Mater. 2011;23:2436-42.
58. Yu MK, Kim D, Lee I-H, So J-S, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011;7:2241-9.
59. Srinivas M, Aarntzen EH, Bulte JW, et al. Imaging of cellular therapies. Adv Drug Deliv Rev. 2010;62:1080-93.
60. Roach 3rd M, Alberini JL, Pecking AP, et al. Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions. J Surg Oncol. 2011;103:587-601.
61. Spencer SS, Theodore WH, Berkovic SF. Clinical applications: MRI, SPECT, and PET. Magn Reson Imag. 1995;13:1119-24.
62. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005;23:1407-13.
63. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magneto-vaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 2009;69:3180-7.
64. Singh N, Jenkins GJ, Asadi R, Doak SH. Potential toxicity of super-paramagnetic iron oxide nanoparticles (SPION). Nano Rev 2010;1:5358. doi:10.3402/nano.v1i0.5358.